Innovative Oral Treatments of Uterine Leiomyoma

被引:40
作者
Sabry, Mohamed [1 ,2 ]
Al-Hendy, Ayman [3 ]
机构
[1] Meharry Med Coll, Ctr Women Hlth Res CWHR, Nashville, TN 37208 USA
[2] Sohag Univ, Fac Med, OB GYN Dept, Sohag 82524, Egypt
[3] George Hubbard Hosp, Meharry Med Coll, Ctr Women Hlth Res, Dept Obstet & Gynecol, 1005 Dr DB Todd Jr Blvd,5th Floor,Room 5131C, Nashville, TN 37208 USA
关键词
D O I
10.1155/2012/943635
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Uterine fibroids (leiomyoma), the benign tumors of the uterine wall, are very common cause of morbidity in reproductive age women usually in the form of excessive vaginal bleeding, chronic pelvic pain, miscarriage and infertility. These tumors are the leading indication for hysterectomy in the United States. Uterine fibroids are about 4 times higher in blacks compared to whites and constitute a major health disparity challenge. The estimated cost of uterine fibroids is up to $ 34.4 billion annually. Additionally, women who suffer from this disease and desire to maintain their future fertility have very limited treatment choices. Currently, there is no effective long-term medicinal treatment for uterine fibroids. While surgery has traditionally been the gold standard for the treatment of uterine fibroids, there is growing interest towards orally administered medications for the management of leiomyoma-related symptoms. In this review, we will discuss these promising innovative oral medical treatments in detail.
引用
收藏
页数:10
相关论文
共 107 条
[1]  
Abbott, 2011, FUT ABB PIP
[2]   SERUM VITAMIN D3 LEVEL INVERSELY CORRELATES WITH TOTAL FIBROID TUMOR BURDEN IN WOMEN WITH SYMPTOMATIC UTERINE FIBROID. [J].
Abdelraheem, M. S. ;
Al-Hendy, A. .
FERTILITY AND STERILITY, 2010, 94 (04) :S74-S74
[3]   Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate [J].
Ahmad, N ;
Cheng, PY ;
Mukhtar, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 275 (02) :328-334
[4]   Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels [J].
Amant, F ;
Huys, E ;
Geurts-Moespot, A ;
Lindeque, BG ;
Vergote, I ;
Sweep, F ;
Schoenmakers, EFPM .
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2003, 10 (02) :105-109
[5]  
American College of Obstetricians and Gynecologists, 2008, Obstet Gynecol, V112, P387, DOI 10.1097/AOG.0b013e318183fbab
[6]  
[Anonymous], 2009, Prescrire Int, V18, P247
[7]   American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction [J].
不详 .
GYNECOLOGIC ONCOLOGY, 2009, 115 (01) :132-134
[8]   In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone [J].
Attardi, BJ ;
Burgenson, J ;
Hild, SA ;
Reel, JR .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 88 (03) :277-288
[9]   Survival of blacks and whites after a cancer diagnosis [J].
Bach, PB ;
Schrag, D ;
Brawley, OW ;
Galaznik, A ;
Yakren, S ;
Begg, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (16) :2106-2113
[10]   Mifepristone: a novel estrogen-free daily contraceptive pill [J].
Baird, DT ;
Brown, A ;
Cheng, LN ;
Critchley, HOD ;
Lin, SQ ;
Narvekar, N ;
Williams, ARW .
STEROIDS, 2003, 68 (10-13) :1099-1105